Clinical Trial Update: Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy

View source ↗

Summary

PTC Therapeutics' deflazacort (Emflaza) Expanded Access Program for Duchenne Muscular Dystrophy has been approved for marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• EMFLAZA (deflazacort)

Snippet

Sponsor: PTC Therapeutics | Conditions: Duchenne Muscular Dystrophy | Status: APPROVED_FOR_MARKETING